Mabwell Signed an Agreement with Junshi Biosciences

Mabwell Signed an Agreement with Junshi Biosciences Release time：Aug 28, 2017

The "Recombinant Human Anti-TNF-α Monoclonal Antibody Injection Cooperative Development Agreement" was signed with Shanghai Junshi Bio-pharmaceutical Co., Ltd. to jointly conduct preclinical research of a recombinant human anti-TNF-α monoclonal antibody injection.

Hot News

Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders
Mabwell Secures Pakistan's First Denosumab Injection Approval
First-in-Human Study Results of Mabwell's Novel Anti-ST2 Monoclonal Antibody 9MW1911 Selected for ERS 2025 Presentation
Mabwell Announces NMPA Acceptance of IND Application for Novel Anti-IL-11 mAb 9MW3811 in Pathological Scarring
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA
Mabwell Announces First Patient Dosed in the US Clinical Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs